Fosamax History and Development: How Alendronate Changed Osteoporosis Treatment

Early Bisphosphonate Research and Merck's Synthesis of Alendronate

Bisphosphonates originated not in a medical lab but in the water-treatment industry. Their story began with pyrophosphates, compounds used since the 1860s to prevent calcium carbonate scaling in pipes and boilers. Herbert Fleisch and colleagues at the University of Bern recognized in the mid-1960s that pyrophosphate analogs could inhibit pathological calcification in bone tissue [1]. That observation set a new class of drugs in motion.

The first-generation bisphosphonates, etidronate and clodronate, showed anti-resorptive activity but carried a serious limitation: at therapeutic doses, they also impaired bone mineralization. Merck's research team sought a compound that would suppress osteoclast activity without weakening newly formed bone. In the late 1970s and early 1980s, medicinal chemist Gideon Rodan and his collaborator at Merck, Michael Rosenblatt, identified alendronate sodium (originally designated MK-217) as a nitrogen-containing bisphosphonate with potency roughly 700 times greater than etidronate in rat models [2]. The amino group on the side chain proved critical. It gave alendronate a distinct mechanism of action that separated bone resorption inhibition from mineralization toxicity.

Preclinical studies in the late 1980s confirmed that alendronate selectively accumulated at sites of active bone remodeling, was internalized by osteoclasts during resorption, and disrupted intracellular signaling without killing osteoblasts [3]. These findings justified Phase I human trials in the early 1990s.

How Alendronate Works at the Molecular Level

Alendronate inhibits a single enzyme: farnesyl pyrophosphate synthase (FPPS). That is the core of its pharmacology. FPPS sits in the mevalonate pathway, the same biosynthetic cascade that produces cholesterol (and the same pathway statins target at a different step). By blocking FPPS, alendronate prevents the prenylation of small GTPases, including Ras, Rho, and Rac, inside osteoclasts [4].

Without prenylated GTPases, osteoclasts cannot form the ruffled border they need to resorb bone. Their cytoskeletal organization collapses. The cells lose the ability to attach to the bone surface, secrete acid, and dissolve hydroxyapatite. Over days to weeks, affected osteoclasts undergo apoptosis [4].

A useful analogy: if osteoclasts are demolition crews, FPPS inhibition removes their tools and hardhats simultaneously. The cells sit idle, then shut down. Bone formation by osteoblasts continues at a reduced but ongoing rate, so net bone density increases over time.

Alendronate's binding affinity for hydroxyapatite is high. Once deposited in bone mineral, it has an estimated skeletal half-life of approximately 10.5 years [5]. This prolonged retention explains why antiresorptive effects persist for months to years after drug discontinuation. It also explains why the drug distributes almost exclusively to bone tissue, with minimal systemic exposure once it leaves the bloodstream. Oral bioavailability is approximately 0.7%, and even that fraction requires fasting administration with plain water to avoid chelation with food or calcium [6].

The FIT Trial: Proof That Fractures Could Be Prevented

Before the Fracture Intervention Trial (FIT), no oral osteoporosis drug had demonstrated fracture reduction in a large, randomized, placebo-controlled study. FIT changed the standard of evidence.

FIT enrolled 6,459 postmenopausal women aged 55 to 81 across two arms. The vertebral fracture arm (FIT-1) included 2,027 women with at least one existing vertebral fracture at baseline. Over three years, alendronate 5 mg daily (increased to 10 mg at year two) reduced new vertebral fractures by 47% compared to placebo (relative risk 0.53 to 95% CI 0.41 to 0.68) [7]. Hip fracture incidence fell by 51% in this cohort.

The clinical fracture arm (FIT-2) enrolled 4,432 women with low bone mineral density but no baseline vertebral fracture. Results showed a 44% reduction in radiographic vertebral fractures over four years [8]. Hip fracture reduction was 21% overall and did not reach statistical significance in this lower-risk group.

Dr. Dennis Black, the trial's principal investigator at UCSF, described the results: "FIT established that pharmacologic intervention could meaningfully reduce the clinical burden of osteoporotic fractures, not just improve bone density numbers on a DXA scan" [7].

These numbers mattered beyond their statistical significance. Before FIT, physicians often treated osteoporosis with calcium, vitamin D, and the hope that hormone replacement therapy was enough. FIT provided the evidence that a targeted pharmacologic agent could prevent the fractures that cause the morbidity and mortality of osteoporosis.

FDA Approval and the Shift From Daily to Weekly Dosing

The FDA approved alendronate sodium 10 mg daily tablets on September 29, 1995, for the treatment of postmenopausal osteoporosis [9]. Merck marketed the drug under the brand name Fosamax. In 1996, the FDA expanded the indication to include osteoporosis prevention (5 mg daily). By 1997, additional approvals covered glucocorticoid-induced osteoporosis and osteoporosis in men.

Daily dosing created a compliance problem. Patients had to take the pill first thing in the morning, with 6 to 8 ounces of plain water, then remain upright and avoid all food, drink, and other medications for at least 30 minutes. Many could not sustain this routine. One-year adherence rates for daily oral bisphosphonates hovered around 50% in real-world pharmacy data [10].

Merck's solution was a once-weekly formulation. A head-to-head study by Schnitzer and colleagues randomized 1,258 postmenopausal women to alendronate 70 mg once weekly or 10 mg daily for one year. Both regimens produced equivalent increases in lumbar spine BMD (roughly 5.1% vs. 5.4%) and equivalent suppression of bone turnover markers, including N-telopeptide and bone-specific alkaline phosphatase [11]. Gastrointestinal adverse event rates were comparable between groups.

The FDA approved the 70 mg weekly tablet in October 2000. Adoption was rapid. Within two years, weekly Fosamax accounted for the majority of new bisphosphonate prescriptions in the United States. The 2003 National Osteoporosis Foundation guidelines formally recommended weekly dosing as the preferred bisphosphonate regimen, citing improved adherence without loss of efficacy [12].

A Fosamax Plus D formulation (70 mg alendronate combined with 2 to 800 IU or 5 to 600 IU cholecalciferol) received approval in 2005. It addressed the common clinical scenario in which osteoporosis patients were also vitamin D insufficient, reducing the pill burden by one step.

Long-Term Safety: The FLEX Trial and Beyond

Every drug that stays in bone for a decade raises a question: how long should patients take it? The Fracture Intervention Trial Long-term Extension (FLEX) was designed to answer.

FLEX re-enrolled 1,099 women from the original FIT study who had taken alendronate for a mean of five years. They were randomized to continue alendronate 5 mg or 10 mg daily or switch to placebo for five more years, making it a 10-year dataset. Results, published in JAMA in 2006, showed that women who continued alendronate had modestly higher BMD at the hip and spine, but the group that discontinued to placebo maintained stable BMD and showed no statistically significant increase in nonvertebral fractures [13].

One exception: clinical vertebral fractures. Women who continued alendronate had a 55% lower risk of clinical vertebral fractures compared to the placebo group (relative risk 0.45 to 95% CI 0.24 to 0.85) [13]. This finding became the basis for risk-stratified "drug holiday" recommendations that the field still uses today.

The Endocrine Society's 2019 clinical practice guideline summarized the approach: "After 5 years of oral bisphosphonate therapy, reassess fracture risk. Patients at high risk (T-score <-2.5 at the hip, prior vertebral fracture, or high FRAX score) should continue treatment. Others may take a bisphosphonate holiday of up to 5 years" [14].

Two rare adverse events drew public attention during the post-marketing period. Osteonecrosis of the jaw (ONJ) was first reported in bisphosphonate-treated patients in 2003, primarily in cancer patients receiving high-dose intravenous formulations. In the oral osteoporosis-dose population, estimated incidence ranges from 1 in 10,000 to 1 in 100,000 patient-years [15]. Atypical femoral fractures (AFFs), subtrochanteric stress fractures associated with prolonged cortical suppression of remodeling, were identified in case series beginning around 2007. The absolute risk remains low: an analysis of Kaiser Permanente data estimated 1.78 AFFs per 100,000 person-years for the first two years of bisphosphonate use, rising to 113 per 100,000 person-years after eight or more years [16]. These findings reinforced the rationale for periodic treatment reassessment rather than indefinite use.

Patent Expiration and the Generic Era

Merck's U.S. patent on alendronate sodium expired in February 2008. Generic manufacturers, including Teva, Barr Pharmaceuticals, and several others, launched 10 mg daily and 70 mg weekly formulations at a fraction of the brand-name cost. Within months, generic alendronate became one of the most affordable osteoporosis treatments available.

Before patent expiration, brand-name Fosamax cost approximately $80 to $100 per month at U.S. retail pharmacies. Generic 70 mg weekly tablets dropped below $10 per month and, by the mid-2010s, were available for under $4 at several major pharmacy chains [17]. This pricing made alendronate the default first-line pharmacologic option for osteoporosis on virtually every major formulary, including Medicare Part D plans and the VA National Formulary.

Dr. Ethel Siris, director of the Toni Stabile Osteoporosis Center at Columbia University, noted the practical impact: "Generic alendronate removed the cost barrier that had kept many patients from starting or continuing bisphosphonate therapy. It became the statin of bone health" [18].

Peak sales for brand-name Fosamax reached approximately $3.2 billion in 2007, making it one of Merck's top-selling drugs. After generic entry, Merck's revenues from the franchise declined sharply, but global utilization of alendronate increased as more health systems adopted it.

Where Alendronate Stands in Current Clinical Practice

Three decades after its approval, alendronate remains the most commonly prescribed drug for osteoporosis worldwide. The American Association of Clinical Endocrinologists (AACE) and the Endocrine Society both list oral bisphosphonates (alendronate or risedronate) as first-line pharmacologic therapy for postmenopausal osteoporosis in patients at moderate fracture risk [14].

Its position is not unchallenged. Denosumab (Prolia), a RANKL inhibitor approved in 2010, offers injection-based dosing every six months and does not require fasting. Romosozumab (Evenity), an anti-sclerostin antibody approved in 2019, builds bone anabolically before transition to an antiresorptive. Both are typically reserved for patients at very high fracture risk or those who cannot tolerate oral bisphosphonates, largely because of cost. A single Prolia injection runs approximately $900 to $1,800 without insurance, while generic alendronate costs $4 to $15 per month [17].

For the estimated 10 million Americans with osteoporosis and the 44 million with low bone density, alendronate's combination of strong fracture-reduction evidence, decades of safety data, oral convenience, and rock-bottom generic pricing keeps it in the starting lineup. Newer agents may offer advantages in specific high-risk populations, but no drug has displaced alendronate as the entry point for osteoporosis pharmacotherapy.

The 2023 update to the AACE osteoporosis guidelines reinforced this: oral bisphosphonates remain appropriate initial therapy for patients with osteoporosis at moderate fracture risk, with reassessment at 5 years to determine whether to continue, switch, or pause treatment [19]. Clinicians initiating alendronate should ensure adequate calcium intake (1,000 to 1 to 200 mg daily), vitamin D repletion to a serum 25-hydroxyvitamin D level of 30 ng/mL or above, and proper administration technique (upright position, plain water, 30-minute fast) to maximize absorption and minimize esophageal irritation.